StockNews.AI
PLRX
StockNews.AI
159 days

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

1. Faruqi & Faruqi is investigating potential claims against Pliant Therapeutics. 2. Pliant paused enrollment in its BEACON-IPF Phase 2b trial. 3. Stock price fell 60.59% to $3.07 after trial announcement. 4. Analysts downgraded Pliant citing uncertainty around bexotegrast's future. 5. The firm encourages affected investors to discuss their legal rights.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The stock experienced a significant drop after trial news, signaling investor panic. Similar past events show rapid price declines following clinical trial failures.

How important is it?

The severity of the loss and ongoing investigation indicates high investor concern that may affect earnings and market behavior.

Why Short Term?

Immediate reactions to trial news often result in quick stock price volatility. Historical examples show stocks often recover in the long run if new prospects arise.

Related Companies

VRTXSPPIAMGN
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Pliant Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information], /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pliant Therapeutics, Inc. ("Pliant" or the "Company") (NASDAQ: PLRX).Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP) On February 7, 2025, Pliant issued a press release "announc[ing] that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF)."  Following this news, Wells Fargo and Citi analysts both downgraded Pliant, citing uncertainty about bexotegrast's path forward. On this news, Pliant's stock price fell $4.72 per share, or 60.59%, to close at $3.07 per share on February 10, 2025.To learn more about the Pliant Therapeutics investigation, go to www.faruqilaw.com/PLRX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).Follow us for updates on LinkedIn, on X, or on Facebook.Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.SOURCE Faruqi & Faruqi, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News